[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transportation-of-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transportation-of-patients":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,74,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100612407","phase-3-tenecteplase-before-interhospital-transfer-for-evt-in-acute-anterior-circulation-lvo-at-45-24-hours-100612407",false,"NCT07253181","Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","Tenecteplase Before inteRhospital Transfer for Endovascular Treatment in pAtientS With acUte Anterior ciRculation Large vEssel Occlusion at 4.5 to 24 Hours","TREASURE","Inclusion Criteria:\n\n* Age of 18 years or older;\n* AIS symptom onset to treatment initiation within 4.5 to 24 hours, stroke onset is defined as the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);\n* Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the internal carotid artery (ICA), MCA (M1 or M2) vessels;\n* Functionally independent (mRS 0-2) prior to stroke onset;\n* Baseline National Institute of Health Stroke Scale (NIHSS) of 6-25;\n* Intended to transfer to ECCs for EVT (patient transfer), or intended to transfer a neurointerventionalist from the ECC for EVT (physician transfer);\n* Written informed consent from patients or legally authorized representatives;\n* Neuroimaging: ICA or M1, M2 occlusion by MRA or CTA AND the target mismatch profile on computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP), defined as an ischemic core volume \\\u003C70mL, mismatch volume ≥15mL and mismatch ratio ≥1.8;\n\nAlternative neuroimaging (if CTP or MRP is technically inadequate or unavailable):\n\nThe presence of a diffusion-weighted imaging (DWI)-fluid-attenuated inversion recovery (FLAIR) mismatch pattern (i.e., acute ischemic lesion visible on DWI but no marked parenchymal hyperintensity visible on FLAIR) OR an Alberta Stroke Program Early CT Score (ASPECTS) score ≥7 on NCCT or MRI scan;\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to any ingredients of Tenecteplase;\n* Intended to receive IVT as standard-of-care therapy;\n* Rapidly improving symptoms with NIHSS score \\\u003C6 before randomization;\n* Any contra-indication for IVT except for the time criterion;\n* Known hereditary or acquired hemorrhagic diathesis;\n* Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, INR \\>1.7 or prothrombin time \\>15s; if use of any direct oral anticoagulant within the last 48 hours; if on any full dose heparin\u002Fheparinoid within the last 24 hours;\n* Ischemic stroke or myocardial infarction in previous 3 months\n* Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months;\n* Severe, uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg);\n* Other serious, advanced or terminal illness with life expectancy less than 6 months;\n* Baseline blood glucose \\\u003C50mg\u002Fdl or \\>400mg\u002Fdl;\n* Contraindication to imaging with contrast agents;\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA or MRA (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion);\n* Extensive early ischemic change on non-contrast CT or MRI-DWI estimated to be \\>1\u002F3 MCA territory, or significant hypodensity outside the Tmax\\>6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria);\n* Evidence of intracranial tumor (mass effect), acute intracranial hemorrhage, or arteriovenous malformation;\n* Current participation in another investigational drug or device study;\n* Suspected endocarditis;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;","ALL","18 Years",{"count":20,"type":21},572,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).\n\n* Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care\n* Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg\u002Fkg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.",[27,28,29],"Acute Ischemic Stroke","Large Vessel Occlusion","Transportation of Patients",[31,32,33],"interhospital transfer","acute ischemic stroke","anterior circulation large vessel occlusion","RECRUITING","2026-03-16",{"date":37,"type":38},"2026-03-19","ACTUAL",{"date":40,"type":38},"2026-01-06",{"date":42,"type":21},"2028-03-30",{"name":44,"class":45},"Xuanwu Hospital, Beijing","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100608850","geographic-analysis-of-cancer-patients-residences-at-delafontaine-hospital-100608850","NCT07206914","Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital","Inclusion Criteria:\n\n\\- Adult patients treated for cancer in the oncology department of Delafontaine Hospital since January 1, 2020.\n\nExclusion Criteria:\n\n\\- Patients whose cancer treatment in the oncology department was completed before 2020.",{"count":54,"type":21},300,"OBSERVATIONAL","This study looks at where cancer patients treated at Delafontaine Hospital live and how far they have to travel for care. By mapping patients' home addresses (anonymized), the research will show how distance, transportation, and social factors affect access to cancer treatments and support services. The goal is to better understand inequalities in access to care and to improve patient support in the future.",[58,59,60,61,62,29],"Neoplasms","Oncology Service","Health Services Accessibility","Health Inequalities","Residence Characteristics","NOT_YET_RECRUITING","2025-09-26",{"date":66,"type":38},"2025-10-03",{"date":68,"type":21},"2025-10-15",{"date":70,"type":21},"2026-04-15",{"name":72,"class":45},"Centre Hospitalier de Saint-Denis",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":55,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100598343","pediatric-intensive-care-transport-registry-100598343","NCT07070258","Pediatric Intensive Care Transport Registry","PIT Registry","Inclusion Criteria:\n\n* Critically ill children aged at least 27 days and a corrected gestational age of over 41 weeks AND\n* Maximum age of 17 years AND\n* Interhospital transport AND\n* Critical care transport by a dedicated critical care transport team using an intensive care ambulance (Type C vehicle) or an air ambulance OR\n* The transport was accompanied by a specialist in intensive care or emergency medicine. OR\n* The in-hospital destination of the transport is a critical care area, such as an intensive care unit, a trauma room, a resuscitation area, an operating theatre, an emergency imaging procedure or an emergency intervention.","27 Days","17 Years",{"count":84,"type":21},1000,"1 Day","The aim is to establish a nationwide registry for pediatric intensive care transports in Germany. The project aims to describe and analyse the need for, and current practice of, specialised transports. These data could then be used for future demand planning.",[88,29,89],"Critical Care Medicine","Pediatrics",[91,92,93,94],"intensive care transport","critical care transport","pediatrics","registry","2025-07-16",{"date":97,"type":38},"2025-07-20",{"date":99,"type":38},"2024-11-25",{"date":101,"type":21},"2029-12-31",{"name":103,"class":45},"Philipps University Marburg",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":55,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":73},"100586214","to-evaluate-transport-safety-between-different-scanning-methods-for-patients-in-the-intensive-care-unit-icu-100586214","NCT06912464","To Evaluate Transport Safety Between Different Scanning Methods for Patients in the Intensive Care Unit (ICU)","Comparative Safety Analysis: PET vs. CT Scans During Intensive Care Admission","CASA","Inclusion Criteria:\n\n* Patients receiving PET\u002FCT during ICU admission (any indication)\n* Patients undergoing CT Thorax\u002FAbdomen (matched cohort)\n\nExclusion Criteria:\n\n* CT-scan for any acute indication (acute danger to vital parameters).\n* CT-Cerebrum\n* Registrion in the dutch Objection to medical research registry.",{"count":113,"type":21},208,"2 Days","The goal of this study is to assess how safe it is for critically ill patients in the Intensive Care Unit (ICU) to undergo a PET scan. A PET scan is a type of medical imaging used to help determine why a patient is sick. It is similar to a CT scan but involves a small amount of radioactivity to highlight areas of concern in the body.\n\nFor a PET scan, patients need to be transported from the ICU to the scanning room, which can be risky because ICU patients are often very fragile. After a patient gets the PET scan injection, their body gives off a small amount of radiation for a short time. Because of this, doctors and nurses have to keep some distance to protect themselves. This means they keep an eye out for the patient from a bit further away than normal. This makes the procedure slightly riskier, especially for very sick patients.\n\nThis study aims to answer the question:\n\nIs getting a PET scan riskier for ICU patients than a regular CT scan?\n\nAll patients in this study will continue to receive their usual critical care. Researchers will closely monitor the scanning process to evaluate its safety.\n\nPET scans are already widely used to detect cancer, but new advancements may allow us to use them more often to diagnose infections. Before this can become routine practice, we need to ensure that PET scanning is just as safe as other commonly used imaging techniques. This study will assess all ICU patients undergoing a PET scan-regardless of the reason for the scan-to determine how safe the procedure is in critically ill individuals.",[29,117,118],"PET \u002F CT","Intensive Care Medicine",[120,118,121,122,123,124,125],"Intrahospital transport (IHT)","ICU","PET","PET\u002FCT","Safety","CT","2025-03-31",{"date":128,"type":38},"2025-04-04",{"date":130,"type":21},"2025-04-01",{"date":132,"type":21},"2027-04-01",{"name":134,"class":45},"University Medical Center Groningen"]